Skip to main content

Table 1 Correlation of clinical variables and S. aureus clonal complexes

From: High burden of complicated skin and soft tissue infections in the Indigenous population of Central Australia due to dominant Panton Valentine leucocidin clones ST93-MRSA and CC121-MSSA

Variable Overall n = 49
n (%a), median (IQR)
At least one isolate ST93 n = 24
n (%), median (IQR)
At least one isolate CC121 n = 15
n (%), median (IQR)
Other clonal complexes n = 10
n (%), median (IQR)
Demographics
 Ethnicity: Indigenous 44 (89.8) 22 (91.7) 14 (93.3) 8 (80.0)
 Gender: Female 29 (59.2) 12 (50.0) 9 (60.0) 8 (80.0)
 Age (years) 30.0 [10.0, 46.0] 28.5 [11.2, 47.0] 34.0 [24.5, 45.5] 20.5 [4.5, 42.2]
 Residence
  Town camp 12 (24.5) 6 (25.0) 4 (26.7) 2 (20.0)
  Remote community 24 (49.0) 12 (50.0) 6 (40.0) 6 (60.0)
  Prison 1 (2.0)   1 (6.7)  
  Visitor 2 (4.1) 1 (4.2)   1 (10.0)
  House in Alice Springs 10 (20.4) 5 (20.8) 4 (26.7) 1 (10.0)
Co-morbidities
 Diabetes mellitus 22 (44.9) 12 (50.0) 6 (40.0) 4 (40.0)
 Chronic kidney disease 12 (24.5) 6 (25.0) 3 (20.0) 3 (30.0)
 Haemodialysis 2 (4.1) 2 (8.3) 0 (0.0) 0 (0.0)
 Excess alcohol use 6 (12.2) 3 (12.5) 2 (13.3) 1 (10.0)
 Obesity (BMI ≥ 30) 13 (26.5) 3 (12.5) 7 (46.7) 3 (30.0)
 Cardiac failure 6 (12.2) 2 (8.3) 3 (20.0) 1 (10.0)
 Ischaemic heart disease 4 (8.2) 2 (8.3) 1 (6.7) 1 (10.0)
 Scabies 12 (24.5) 5 (20.8) 4 (26.7) 3 (30.0)
 Asthma 5 (10.2) 1 (4.2) 1 (6.7) 3 (30.0)
Healthcare exposure
 Admission in previous 6 months 18 (38.3) 9 (39.1) 5 (33.3) 4 (44.4)
 Previous CA- MRSA 18 (38.3) 10 (43.5) 3 (20.0) 5 (55.6)
Clinical presentation
 Size (cm) 4.0 [3.0, 5.0] 4.0 [2.5, 5.0] 4.0 [3.0, 6.0] 5.5 [3.5, 9.0]
 Duration (days) 5.0 [2.0, 7.0] 5.5 [3.2, 7.0] 4.0 [2.0, 6.5] 3.0 [2.0, 7.0]
 Site of infection
  Head & neck 8 (16.3) 5 (20.8) 3 (20.0)  
  Upper limb 9 (18.4) 7 (29.2) 1 (6.7) 1 (10.0)
  Torso 6 (12.2) 3 (12.5) 13.3 (2)  
  Buttock/groin/thigh 12 (24.5) 6 (25.0) 2 (13.3) 1 (10.0)
  Lower leg 11 (22.4) 2 (8.3) 26.7 (4) 3 (30.0)
  Multiple 3 (6.1) 1 (4.2) 13.3 (2) 5 (50.0)
Treatment
 Time to surgery (days) 1.0 [1.0, 1.0] 1.0 [1.0, 1.0] 1.0 [1.0, 1.0] 1.0 [1.0, 1.0]
 Antimicrobials prior surgery  
  Inactive 18 (36.7) 13 (54.2)   5 (50.0)
  Active 30 (61.2) 10 (41.7) 15 (100.0) 5 (50.0)
 Planned oral antibiotic duration (days) 7.0 [2.0, 7.0] 6.5 [3.2, 7.0] 5.0 [0.0, 7.0] 7.0 [5.5, 7.0]
Clinical outcomes
 Length of stay (days) 3.0 [2.0, 7.0] 3.0 [3.0, 6.0] 2.0 [2.0, 6.5] 3.0 [2.2, 7.0]
 Progression to deep structures 5 (11.9) 3 (15.0) 0 (0.0) 2 (25.0)
 Secondary infection 1 (2.5) 0 (0.0) 1 (7.7) 0 (0.0)
 Return to theatre 6 (12.5) 6 (26.1) 0 (0.0) 0 (0.0)
 Readmission within 30 days 4 (8.3) 2 (8.7) 2 (13.3) 0 (0.0)
 Unscheduled medical review 8 (21.1) 4 (23.5) 2 (15.4) 2 (25.0)
 Repeat antibiotics required 10 (26.3) 3 (17.6) 6 (46.2) 1 (12.5)
Antimicrobial susceptibility
 Methicillin resistance 28 (57.1) 23 (95.8) 0 (0.0) 5 (50.0)
 Clindamycin resistance   3 (12.5) 9 (60.0)  
 Trimethoprim/sulfamethoxazole resistance   0 (0.0) 0 (0.0)  
  1. aCalculation of percentages takes into account missing data points